Portal de Periódicos da CAPES

The Antidiabetic Effect and Pharmacokinetic Properties of Glipizide

1981; Wiley; Volume: 210; Issue: 1-6 Linguagem: Inglês

10.1111/j.0954-6820.1981.tb09796.x

0001-6101

Jan Östman, I Christenson, B. Jansson, Leslie P. Weiner,

Diabetes Treatment and Management

ABSTRACT. In 13 patients with maturity‐onset diabetes mellitus which did not respond to diet therapy alone, serum concentration of glipizide, blood glucose (B‐G) concentration, serum immunoreactive insulin (S‐IRI) and plasma glycerol (P‐G) were monitored hourly over 12 hours after placebo, an initial dose of glipizide (5 mg p.o.) and long‐term treatment with glipizide (range 7.5–20 mg, mean 10.4), which produced fasting B‐G of less than 8 mmol/1. During the long‐term treatment, glipizide was given in a random, cross‐over pattern, either as a single dose in the morning or as a three‐part divided dose regime, in the same total daily amount. The duration of the immediate effects of glipizide on B‐G, S‐IRI and S‐IRI/B‐G was 9, 4.5 and 6.5 hours, respectively. The mean apparent half‐life of glipizide was 4.1 hours, the mean distribution volume 0.13 l/kg and the mean plasma clearance 0.023 l/kg × h. The area under the concentration curve from 7.30 a.m. to 7.30 p.m. was 15% higher after the single dose regime. The serum levels of glipizide at 10 hours were only 30% lower than after the three‐part divided dose regime. There were no significant differences between the single and divided dose regimes as regards B‐G, S‐IRI and S‐IRI/B‐G, although the mean B‐G for the 12‐hour period was somewhat lower after the former than after the latter (7.0 against 8.7 mmol/l).